Mucosal Permeability and Immune Activation as Potential Therapeutic Targets of Probiotics in Irritable Bowel Syndrome

被引:75
|
作者
Barbara, Giovanni
Zecchi, Lisa
Barbaro, Raffaella
Cremon, Cesare
Bellacosa, Lara
Marcellini, Marco
De Giorgio, Roberto
Corinaldesi, Roberto
Stanghellini, Vincenzo
机构
[1] Univ Bologna, Dept Clin Med, I-40138 Bologna, Italy
[2] Univ Bologna, Ctr Appl Biomed Res, I-40138 Bologna, Italy
关键词
irritable bowel syndrome; mast cells; abdominal pain; mucosal barrier; immune activation; RANDOMIZED CONTROLLED-TRIAL; DIARRHEA-PREDOMINANT IBS; CROSS-OVER TRIAL; DOUBLE-BLIND; MAST-CELLS; INTESTINAL PERMEABILITY; FECAL MICROBIOTA; BARRIER FUNCTION; SYMPTOMS; EFFICACY;
D O I
10.1097/MCG.0b013e318264e918
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
There is increasingly convincing evidence supporting the participation of the gut microenvironment in the pathophysiology of irritable bowel syndrome (IBS). Studies particularly suggest an interplay between luminal factors (eg, foods and bacteria residing in the intestine), the epithelial barrier, and the mucosal immune system. Decreased expression and structural rearrangement of tight junction proteins in the small bowel and colon leading to increased intestinal permeability have been observed, particularly in post-infectious IBS and in IBS with diarrhea. These abnormalities are thought to contribute to the outflow of antigens through the leaky epithelium, causing overstimulation of the mucosal immune system. Accordingly, subsets of patients with IBS show higher numbers and an increased activation of mucosal immunocytes, particularly mast cells. Immune factors, released by these cells, including proteases, histamine, and prostanoids, participate in the perpetuation of the permeability dysfunction and contribute to the activation of abnormal neural responses involved in abdominal pain perception and changes in bowel habits. All these mechanisms represent new targets for therapeutic approaches in IBS. Probiotics are an attractive therapeutic option in IBS given their recognized safety and by virtue of positive biological effects they can exert on the host. Of importance for the IBS pathophysiology is that preclinical studies have shown that selective probiotic strains exhibit potentially useful properties including anti-inflammatory effects, improvement of mucosal barrier homeostasis, beneficial effects on intestinal microbiota, and a reduction of visceral hypersensitivity. The effect of probiotics on IBS is positive in most randomized, controlled studies, although the gain over the placebo is small. Identifying tailored probiotic approaches for subgroups of IBS patients represents a challenge for the future.
引用
收藏
页码:S52 / S55
页数:4
相关论文
共 50 条
  • [41] Probiotics and irritable bowel syndrome
    Cong Dai
    Chang-Qing Zheng
    Min Jiang
    Xiao-Yu Ma
    Li-Juan Jiang
    World Journal of Gastroenterology, 2013, 19 (36) : 5973 - 5980
  • [42] Protease-activated receptors: potential therapeutic targets in irritable bowel syndrome?
    Gloro, R
    Ducrotte, P
    Reimund, JM
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (05) : 1079 - 1095
  • [43] Intestinal Permeability in Irritable Bowel Syndrome Patients: Effects of NSAIDs
    Kerckhoffs, Angele P. M.
    Akkermans, Louis M. A.
    de Smet, Martin B. M.
    Besselink, Marc G. H.
    Hietbrink, Falco
    Bartelink, Imke H.
    Busschers, Wim B.
    Samsom, Melvin
    Renooij, Willem
    DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (03) : 716 - 723
  • [44] Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: Future therapeutic targets
    Kraneveld, Aletta D.
    Rijnierse, Anneke
    Nijkamp, Frans P.
    Garssen, Johan
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 585 (2-3) : 361 - 374
  • [45] Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study
    Corinaldesi, R.
    Stanghellini, V.
    Cremon, C.
    Gargano, L.
    Cogliandro, R. F.
    De Giorgio, R.
    Bartesaghi, G.
    Canovi, B.
    Barbara, G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (03) : 245 - 252
  • [46] Colonic Mucosal Immune Activation in Mice with Ovalbumin-Induced Allergic Airway Disease: Association between Allergic Airway Disease and Irritable Bowel Syndrome
    Kim, Sanghyun
    Keum, Bora
    Byun, Junhyoung
    Kim, Byoungjae
    Lee, Kijeong
    Yeon, Jiwoo
    Lee, Jaemin
    Choi, Hyuksoon
    Kim, Eunsun
    Jeen, Yoontae
    Lee, Hongsik
    Chun, Hoonjai
    Kim, Taehoon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (01)
  • [47] Probiotics in irritable bowel syndrome: Where are we?
    Barbara, Giovanni
    Cremon, Cesare
    Azpiroz, Fernando
    NEUROGASTROENTEROLOGY AND MOTILITY, 2018, 30 (12)
  • [48] The Efficacy and Potential Mechanisms of Chinese Herbal Medicine on Irritable Bowel Syndrome
    Bi, Zijuan
    Zheng, Yu
    Yuan, Jianye
    Bian, Zhaoxiang
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (34) : 5163 - 5172
  • [49] Immune Activation in Irritable Bowel Syndrome: Can Neuroimmune Interactions Explain Symptoms?
    Hughes, Patrick A.
    Zola, Heddy
    Penttila, Irmeli A.
    Blackshaw, L. Ashley
    Andrews, Jane M.
    Krumbiegel, Doreen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (07) : 1066 - 1074
  • [50] A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome
    Hoveyda, Nourieh
    Heneghan, Carl
    Mahtani, Kamal R.
    Perera, Rafael
    Roberts, Nia
    Glasziou, Paul
    BMC GASTROENTEROLOGY, 2009, 9